Related Experiment Videos
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists
Alan D Adams1, Zao Hu, Derek von Langen
1Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co. Inc., PO Box 2000 Rahway, NJ 07065, USA. alan_adams@merck.com
Bioorganic & Medicinal Chemistry Letters
|September 3, 2003
Summary
New O-arylmandelic acid agonists targeting peroxisome proliferator-activated receptors (PPARs) effectively lower blood sugar in diabetes models. These compounds avoid common PPAR-gamma side effects, offering a potentially safer treatment for type 2 diabetes.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Endocrinology
Background:
- Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate glucose metabolism and lipid homeostasis.
- PPAR agonists are used to treat type 2 diabetes mellitus (DM2), but often exhibit side effects.
- PPAR-gamma agonists can cause adipose tissue (BAT) proliferation and cardiac hypertrophy.
Purpose of the Study:
- To investigate the anti-hyperglycemic efficacy of a novel class of O-arylmandelic acid PPAR agonists.
- To evaluate the safety profile of these agonists, specifically assessing for PPAR-gamma associated side effects.
Main Methods:
- Synthesis and characterization of novel O-arylmandelic acid derivatives.
- In vivo testing of anti-hyperglycemic effects in a db/db mouse model of DM2.
- In vivo tolerability assessment in a rat model, focusing on BAT and cardiac tissues.
Main Results:
- The novel O-arylmandelic acid PPAR agonists demonstrated excellent anti-hyperglycemic efficacy in db/db mice.
- These PPARalpha-weighted agonists did not induce BAT proliferation or cardiac hypertrophy in rats.
- The results suggest a favorable therapeutic window for these compounds.
Conclusions:
- O-arylmandelic acid PPAR agonists represent a promising new class of anti-diabetic agents.
- These compounds offer potential for improved safety compared to existing PPAR-gamma agonists.
- Further investigation is warranted to explore their clinical utility in managing type 2 diabetes.